<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02807857</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696B3402</org_study_id>
    <secondary_id>2016-000473-20</secondary_id>
    <nct_id>NCT02807857</nct_id>
  </id_info>
  <brief_title>A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care</brief_title>
  <acronym>PREFER</acronym>
  <official_title>A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This low interventional study, whose unique intervention was to measure the blood level of a&#xD;
      biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary&#xD;
      Care Physicians (PCPs) in Europe, assessed if the cardiologist referral guided by NT-proBNP&#xD;
      measurement in patients who were currently judged by PCPs as being stable, would lead to&#xD;
      optimization of HF treatment, defined in adherence to treatment recommendations of the&#xD;
      current European Society of Cardiology guidelines for the treatment of heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the majority of European countries, the primary management of chronic heart failure&#xD;
      patients was performed by General Practitioners in collaboration with cardiologists&#xD;
      (specialists). Previous studies had shown that many patients suffering from CHF do not&#xD;
      receive optimal pharmacological and/or device treatment for their disease. An increase in&#xD;
      natriuretic peptides (BNP, NT-proBNP) was associated with increased risk of cardiovascular&#xD;
      events in heart failure patients. The purpose of the present study was to assess if a&#xD;
      referral of clinical stable chronic heart failure patients with reduced ventricular ejection&#xD;
      fraction (EF &lt; or = 40%) and NT-proBNP level &gt; or = 600 pg/mL to a specialist (cardiologist)&#xD;
      led to treatment optimization, defined as adherence to the treatment recommendations&#xD;
      according to the European Society of Cardiology (ESC) guidelines. In addition, data obtained&#xD;
      in this study was used to describe demographic, clinical (including NT-proBNP levels) and&#xD;
      treatment characteristics of CHF patients who were managed in the primary care setting across&#xD;
      Europe..&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2016</start_date>
  <completion_date type="Actual">March 23, 2018</completion_date>
  <primary_completion_date type="Actual">March 23, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1 (Before Referral to a Cardiologist)</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Assessment of treatment regimen with respect to ESC guideline adherence at Visit 1 before referral to cardiologist. ESC Criteria for adherence: Drug Types: Treatment with (1) ACEi or (1) ARB in combination with (1) beta-blocker and (1) MRA for patients w/an LVEF ≤ 35% at V1. Treatment w/(1) ACEi or (1) ARB, in combination with (1) beta-blocker+ without treatment with an MRA for patients with an LVEF &gt; 35% at visit 1. Drug type &amp; dose: Guideline adherent with respect to drug types and dosage of all respective guideline drugs ≥ 50% of the recommended target dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to ESC Guideline at Visit 2 (After Referral to a Cardiologist, Month 6), for Follow-up Set: Drug Type and Drug Type and Dose</measure>
    <time_frame>Month 6</time_frame>
    <description>Assessment of patients' adherence at Visit 2, for patients who were already adherent at Visit 1, and those who were not adherent at Visit 1, for both drug type and drug type and dose. ESC Criteria for adherence: Drug Types: Treatment with (1) ACEi or (1) ARB in combination with (1) beta-blocker and (1) MRA for patients w/an LVEF ≤ 35% at V1. Treatment w/(1) ACEi or (1) ARB, in combination with (1) beta-blocker+ without treatment with an MRA for patients with an LVEF &gt; 35% at visit 1. Drug type &amp; dose: Guideline adherent with respect to drug types and dosage of all respective guideline drugs ≥ 50% of the recommended target dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Heart Failure</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>The duration of Heart Failure was collected at Baseline (Visit 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Current Use of Concomitant Compound</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Use of concomitant compounds were collected at baseline (Visit 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Follow-Up Patients With Current Use of Concomitant Compound at Visit 2</measure>
    <time_frame>6 months (Visit 2)</time_frame>
    <description>Use of concomitant compounds were collected at 6 months (Visit 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Clinically Stable Patients for Whom the Cardiologist and/or Primary Care Physician Optimizes Treatment Post Referral, Stratified According to Key Baseline Characteristics</measure>
    <time_frame>6 months</time_frame>
    <description>For patients who enter the prospective period of the study the post-referral treatment choice of cardiologists and/or primary care physicians was documented; for patients, for whom the cardiologist and/or primary care physician chose to prescribe a novel Heart Failure treatment, the treatment was assessed, if it fulfills the definition of adherence to European Society of Cardiology (ESC) guideline recommendation. The proportion of patients for whom an ESC guideline adherent treatment was de novo prescribed was assessed stratified according to different parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Different NT-proBNP Level Categories</measure>
    <time_frame>One measurement in all consecutive patients at baseline (Visit 1)</time_frame>
    <description>NT-proBNP levels (pg/ml) was measured at baseline in all consecutive patients who satisfy the inclusion and exclusion criteria. Measurements were performed on-site by means of a handheld device provided for the purposes of the study. NT-proBNP level categories could be 600 -799 pg/ml, 800 - 999 pg/ml, 1000 - 1200 pg/ml, &gt; 1200 pg/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Clinically Stable Patients</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Clinically stable patients in this study were defined as those patients for whom the primary care physician did not see a necessity (based on signs and symptoms of HF) to change the current pharmacological and/or device treatment of HF and who were on stable pharmacological and/or device treatment for HF for at least 3 months prior to inclusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients by Cardiologist Prescription Practice Per Country/Region</measure>
    <time_frame>6 months</time_frame>
    <description>The cardiologists' suggestions for pharmacological and/or device therapy for the treatment of clinically stable CHF patients was documented and assessed by means of descriptive statistical measures stratified by country/region 6 months after baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of NT-proBNP Levels in Clinically Stable Chronic Heart Failure Patients With and Without Treatment Optimization 10 Months After Baseline</measure>
    <time_frame>10 months</time_frame>
    <description>At 10 months after baseline (end of study) NT-proBNP was assessed in clinically stable CHF patients with baseline NT-proBNP levels ≥ 600 pg/ml. Thus, for those patients two NT-proBNP measurements were available: at baseline and 10 months later. The individual change of NT-proBNP between both time points were assessed in accordance to the patients' treatment history during the study, i.e. baseline Heart Failure treatment and therapeutic decision taken 6 months after baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQol Five Dimensions Questionnaire (EQ-5D) Total and Individual Sub-scores at Visit 1 (Baseline), Visit 2 (6 Months) and Visit 3 (10 Months)</measure>
    <time_frame>Baseline (Visit 1), 6 months (Visit 2), 10 months (Visit 3)</time_frame>
    <description>Quality of life (QoL) was assessed by EQ-5D including the dimensions mobility, self-care, usual activity, pain/discomfort, anxiety/depression. A utility index based on UK value sets was built to summarize the information of these five dimensions into a single scale. The utility index can range between -0.281 and 1.0 where a higher number indicates a better health status. In addition, a visual analog scale (VAS) was applied with a possible range between 0 (=worst imaginable health state) and 100 (=best imaginable health state). Scores collected for all patients at baseline (Visit 1) and at Visit 2 and Visit 3 (only patients who entered the prospective period of the study, i.e. clinically stable patients with a NT-proBNP level ≥ 600 pg/ml) were asked to fill out the EuroQol 5D (EQ-5D) quality of life (QoL) questionnaire validated for heart failure (HF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total and Individual Sub-scores at Visit 1 (Baseline), Visit 2 (6 Months) and Visit 3 (10 Months)</measure>
    <time_frame>Baseline (Visit 1), 6 months (Visit 2), 10 months (Visit 3)</time_frame>
    <description>The KCCQ is a self-administered questionnaire. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and quality of life, each with different Likert scale wording, including limitations, frequency, bother, change in condition, understanding, levels of enjoyment and satisfaction. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. A positive change from baseline indicates improvement. Scores were collected for all patients at baseline and Visit 2 and Visit 3 (only patients who had entered the prospective period of the study (clinically stable patients with a NT-proBNP level ≥ 600 pg/ml) were asked to complete Kansas City Cardiomyopathy Questionnaire (KCCQ) validated for Heart Failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Different Living Conditions</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Living conditions were collected at Baseline (Visit 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Different Employment Status</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Employment status was collected at Baseline (Visit 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Smoking Status</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Smoking status was collected at baseline (visit 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients From Different Geographical Regions</measure>
    <time_frame>Baseline (visit 1)</time_frame>
    <description>Geographic regions were collected at Baseline (Visit 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Health Insurance Status</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Health insurance status was collected at Baseline (Visit 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients at Different Educational Level</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Educational level was collected at Baseline (Visit 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Per Primary Etiology of Heart Failure</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>The primary etiology of Heart Failure was collected at Baseline (Visit 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Heart Failure (HF)-Related Hospitalizations in the Previous 12 Months Prior to Baseline, and During the Study</measure>
    <time_frame>Baseline (Visit 1), 6 months, 10 months</time_frame>
    <description>HF-related hospitalizations was collected in the previous 12 months prior to baseline at baseline visit, at 6 and 10 months post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Cardiovascular and Non-cardiovascular Co-morbidities</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Cardiovascular and non-cardiovascular co-morbidities were collected at baseline (Visit 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Dose of Previously Taken and Current Use of Concomitant Medications</measure>
    <time_frame>Baseline (Visit 1), 6 months, 10 months</time_frame>
    <description>Mean Dose of previously taken and current use of concomitant medications was to be collected at Visit 1, 6 months, 10 months post-baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Heart Failure (HF) Treatment Combinations</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>The types and number of participants with HF treatment combinations were collected at Baseline (Visit 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment With Device Type</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>The duration of treatment with device type was collected at baseline (Visit 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Previously Taken and Currently Use of Most Common Non-Heart Failure Concomitant Compounds</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Duration of most common previously taken and current use of most common Non-HF concomitant compounds were collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients by Primary Care Physicians' Prescription Practice Per Country/Region</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>For clinically stable CHF patients, the primary care physicians' prescription of pharmacological and device treatment for HF was to be documented prior to baseline and post cardiologist-referral. At the post-referral visit the degree of implementation of cardiologist-recommendations and the medical decision making (e.g. reasons for non-implementation) were to be documented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1415</enrollment>
  <condition>Chronic Heart Failure (CHF)</condition>
  <arm_group>
    <arm_group_label>Patients' heart failure and non-heart failure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No treatments are stipulated by this protocol - patients' HF and non-HF treatments will be observed throughout the study. The patients' treatment is entirely in the discretion of the primary care physicians</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Patients will receive the treatment that their primary care physician has decided to prescribe for their disease</description>
    <arm_group_label>Patients' heart failure and non-heart failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent and accept study procedures and&#xD;
             time schedule.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Patients suffering from chronic heart failure (the heart failure diagnosis must have&#xD;
             been made or confirmed by a cardiologist and/or hospital physician at any time in the&#xD;
             patient's medical history).&#xD;
&#xD;
          -  Patients with reduced ejection fraction (≤ 40%) as confirmed at any time point in the&#xD;
             patient's medical history.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of investigational drugs either within 5 half-lives of enrollment, or within 30&#xD;
             days, or until the expected pharmacodynamic effect has returned to baseline, whichever&#xD;
             is longer.&#xD;
&#xD;
          -  Major surgery in the last 3 months prior to baseline or planned major surgery or&#xD;
             cardiac intervention during the study.&#xD;
&#xD;
          -  Cancer or other significant co-morbidities implying that the patient's condition is&#xD;
             unstable.&#xD;
&#xD;
          -  Comorbidities that can be associated with elevated natriuretic peptide (NP) levels:&#xD;
             renal insufficiency, (eGFR &lt; 25 ml/min/1.73 m² calculated according to MDRD formula),&#xD;
             recent (less than 3 months) cerebral trauma or recent (less than 3 months)&#xD;
             cerebrovascular incident, novel diagnosis or acute exacerbation of COPD within the&#xD;
             last 3 months.&#xD;
&#xD;
          -  Patients who are primarily managed and regularly followed-up by a cardiologist for&#xD;
             their HF&#xD;
&#xD;
          -  Highly frail patients whose estimated lifespan due to comorbidities by the judgement&#xD;
             of the investigator is less than 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Binkom</city>
        <state>BEL</state>
        <zip>3211</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gozee</city>
        <state>BEL</state>
        <zip>6534</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linkebeek</city>
        <state>BEL</state>
        <zip>1630</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oostham</city>
        <state>BEL</state>
        <zip>3945</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zichem</city>
        <state>BEL</state>
        <zip>3271</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aarschot</city>
        <zip>3200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alveringem</city>
        <zip>8691</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boezinge</city>
        <zip>8904</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxe</city>
        <zip>1080</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buggenhout, Belgium</city>
        <zip>9255</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deinze</city>
        <zip>9800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deurne</city>
        <zip>2100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Diksmuide</city>
        <zip>8600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ezemaal-Neerwinden</city>
        <zip>3400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hasselt, Belgium</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herzele</city>
        <zip>9550</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kluisbergen</city>
        <zip>9690</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Landen</city>
        <zip>3400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leefdaal</city>
        <zip>3060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linkebeek</city>
        <zip>1630</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lommel</city>
        <zip>3920</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maasmechelen</city>
        <zip>3630</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mont sur Marchienne</city>
        <zip>6032</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nazareth</city>
        <zip>9810</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>OOsteeklo</city>
        <zip>9988</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oostende</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oudenaarde</city>
        <zip>9700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Medard</city>
        <zip>6887</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stoumont</city>
        <zip>4987</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tessenderlo</city>
        <zip>3980</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thuilles</city>
        <zip>6536</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tielt-Winge</city>
        <zip>3390</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tremelo</city>
        <zip>3120</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilvoorde</city>
        <zip>1800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waregem</city>
        <zip>8790</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rijeka</city>
        <state>HRV</state>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Visnjevac</city>
        <state>HRV</state>
        <zip>31220</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <state>HRV</state>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bizovac</city>
        <zip>31222</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HRV</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HRV</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HRV</city>
        <zip>42000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HRV</city>
        <zip>44320</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krasica</city>
        <zip>51224</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Slavonski Brod</city>
        <zip>35000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Velika Kopanica</city>
        <zip>35221</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Viskovo</city>
        <zip>51216</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nicosia</city>
        <zip>2048</zip>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nicosia</city>
        <zip>2540</zip>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Præstø</city>
        <zip>4720</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skive</city>
        <zip>7800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Someru</city>
        <state>EST</state>
        <zip>44201</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paide</city>
        <zip>72713</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>11911</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13415</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bersee</city>
        <zip>59254</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breteuil Sur Seine</city>
        <zip>27160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cannes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chantepie</city>
        <zip>35135</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Colombiers</city>
        <zip>31770</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coursan</city>
        <zip>11110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erquy</city>
        <zip>22430</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Seyne-sur-Mer</city>
        <zip>83500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Laval</city>
        <zip>53000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Les Pennes Mirabeau</city>
        <zip>13170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Negrepelisse</city>
        <zip>82800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orthez</city>
        <zip>64300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosiers d'Egleton</city>
        <zip>19300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salles</city>
        <zip>33770</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Six Fours</city>
        <zip>83140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St orens de Gameville</city>
        <zip>31650</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balatonkeresztur</city>
        <zip>8647</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1136</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Csongrad</city>
        <zip>6640</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erd</city>
        <zip>2030</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Felsorajk</city>
        <zip>8767</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hosszuheteny</city>
        <zip>7694</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Korondi</city>
        <zip>6726</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pecs</city>
        <zip>7632</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szabadsag</city>
        <zip>6756</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged-Szoreg</city>
        <zip>H-6771</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torokbalint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zakanyszek</city>
        <zip>6787</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beer Sheva</city>
        <zip>8477713</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grumello Del Monte</city>
        <state>BG</state>
        <zip>24064</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gatteo</city>
        <state>FC</state>
        <zip>47043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jelgava</city>
        <state>LVA</state>
        <zip>LV-3001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <state>LVA</state>
        <zip>LV 1010</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>1012</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1021</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LTU</state>
        <zip>LT 45488</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LTU</state>
        <zip>LT 50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <state>LTU</state>
        <zip>92304</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alytus</city>
        <zip>LT-62386</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-49387</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-49449</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xaghra</city>
        <state>Gozo</state>
        <zip>XRA 2405</zip>
        <country>Malta</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xewkija</city>
        <state>Gozo</state>
        <zip>VCT 110</zip>
        <country>Malta</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rabat</city>
        <country>Malta</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Flisa</city>
        <zip>2270</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Honefoss</city>
        <zip>3515</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kirkenær</city>
        <zip>2260</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lierskogen</city>
        <zip>N-3420</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Loten</city>
        <zip>2340</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lørenskog</city>
        <zip>1473</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Noetteroey</city>
        <zip>3163</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostereidet</city>
        <zip>5993</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skien</city>
        <zip>3734</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelm</city>
        <state>POL</state>
        <zip>22-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kartuzy</city>
        <state>POL</state>
        <zip>83-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <state>POL</state>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-746</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-867</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielawa</city>
        <zip>58-260</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dzierzoniow</city>
        <zip>58-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-018</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>30 415</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-664</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-061</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miasteczko Slaskie</city>
        <zip>42-610</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-388</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-493</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-887</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>03 185</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wielen</city>
        <zip>64-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>54-703</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zgierz</city>
        <zip>95-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seixal</city>
        <state>Bairro Novo</state>
        <zip>2840 481</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cantanhede</city>
        <zip>3060 123</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leca da Palmeira</city>
        <zip>4450 586</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1200 375</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1250 210</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1800 192</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oeiras</city>
        <zip>2780 163</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>121374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127206</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St.- Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ufa</city>
        <zip>450000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vladivostok</city>
        <zip>690002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ivancna Gorica</city>
        <zip>1295</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kranj</city>
        <zip>4000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pesnica pri Mariboru</city>
        <zip>2211</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Slovenske Konjice</city>
        <zip>3210</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spodnji Duplek</city>
        <zip>2241</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vrhnika</city>
        <zip>1360</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zalec</city>
        <zip>3310</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambre</city>
        <state>A Coruna</state>
        <zip>15660</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto do Son</city>
        <state>A Coruña</state>
        <zip>15970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrer</city>
        <state>Alicante</state>
        <zip>03610</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Parador De Las Hortichiuela</city>
        <state>Almeria</state>
        <zip>04720</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El canaveral</city>
        <state>Caceres</state>
        <zip>10820</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puerto Real</city>
        <state>Cadiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burriana</city>
        <state>Castellon</state>
        <zip>12530</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alcudia</city>
        <state>Islas Baleares</state>
        <zip>07400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Telde</city>
        <state>Las Palmas De Gran Canaria</state>
        <zip>35215</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parla</city>
        <state>Madrid</state>
        <zip>28982</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>A Estrada</city>
        <state>Pontevedra</state>
        <zip>36681</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monteporeiro</city>
        <state>Pontevedra</state>
        <zip>36162</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <zip>03540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coruna</city>
        <zip>15007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28030</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28032</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Panxon</city>
        <zip>36340</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>Cyprus</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malta</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <results_first_submitted>March 21, 2019</results_first_submitted>
  <results_first_submitted_qc>December 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>low-interventional observational study,</keyword>
  <keyword>CHF,</keyword>
  <keyword>heart failure,</keyword>
  <keyword>primary care,</keyword>
  <keyword>ESC guidelines,</keyword>
  <keyword>Europe,</keyword>
  <keyword>NT-proBNP,</keyword>
  <keyword>reduced ventricular ejection fraction (EF),</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02807857/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02807857/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The enrolled set consisted of 1415 patients. 861 patients were referred to a cardiologist within this study and Based on findings from the interim-analysis, Novartis decided to terminate the study prematurely in March 2018.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Enrolled Patients</title>
          <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe. Patients who were considered clinically stable with NT-proBNP levels &gt; 600 pg/ml were described and analyzed in the Follow-Up set.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enrolled Set</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1415"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="864"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="551"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patients not suitable for follow-up.</title>
              <participants_list>
                <participants group_id="P1" count="551"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up Set</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="864"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="680"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Terminated By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enrolled Patients</title>
          <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe. Patients who were considered clinically stable an with NT-proBNP levels &gt; 600 pg/ml were referred to a cardiologist for evaluation and were in the follow-up set.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1415"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.8" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <population>Enrolled Set</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years to &lt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥75 years to &lt;85 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥85 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="436"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1282"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1 (Before Referral to a Cardiologist)</title>
        <description>Assessment of treatment regimen with respect to ESC guideline adherence at Visit 1 before referral to cardiologist. ESC Criteria for adherence: Drug Types: Treatment with (1) ACEi or (1) ARB in combination with (1) beta-blocker and (1) MRA for patients w/an LVEF ≤ 35% at V1. Treatment w/(1) ACEi or (1) ARB, in combination with (1) beta-blocker+ without treatment with an MRA for patients with an LVEF &gt; 35% at visit 1. Drug type &amp; dose: Guideline adherent with respect to drug types and dosage of all respective guideline drugs ≥ 50% of the recommended target dose.</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Enrolled and Follow-up Set included. Due to missing left ventricular ejection fraction (LVEF) values, some patients could not be classified.</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1 (Before Referral to a Cardiologist)</title>
          <description>Assessment of treatment regimen with respect to ESC guideline adherence at Visit 1 before referral to cardiologist. ESC Criteria for adherence: Drug Types: Treatment with (1) ACEi or (1) ARB in combination with (1) beta-blocker and (1) MRA for patients w/an LVEF ≤ 35% at V1. Treatment w/(1) ACEi or (1) ARB, in combination with (1) beta-blocker+ without treatment with an MRA for patients with an LVEF &gt; 35% at visit 1. Drug type &amp; dose: Guideline adherent with respect to drug types and dosage of all respective guideline drugs ≥ 50% of the recommended target dose.</description>
          <population>Enrolled and Follow-up Set included. Due to missing left ventricular ejection fraction (LVEF) values, some patients could not be classified.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Level 1: Drug Type : Adherent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Level 1: Drug type : Not Adherent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="802"/>
                    <measurement group_id="O2" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients missing LVEF values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503"/>
                    <measurement group_id="O2" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adherence to ESC Guideline at Visit 2 (After Referral to a Cardiologist, Month 6), for Follow-up Set: Drug Type and Drug Type and Dose</title>
        <description>Assessment of patients' adherence at Visit 2, for patients who were already adherent at Visit 1, and those who were not adherent at Visit 1, for both drug type and drug type and dose. ESC Criteria for adherence: Drug Types: Treatment with (1) ACEi or (1) ARB in combination with (1) beta-blocker and (1) MRA for patients w/an LVEF ≤ 35% at V1. Treatment w/(1) ACEi or (1) ARB, in combination with (1) beta-blocker+ without treatment with an MRA for patients with an LVEF &gt; 35% at visit 1. Drug type &amp; dose: Guideline adherent with respect to drug types and dosage of all respective guideline drugs ≥ 50% of the recommended target dose.</description>
        <time_frame>Month 6</time_frame>
        <population>Follow-Up set</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to ESC Guideline at Visit 2 (After Referral to a Cardiologist, Month 6), for Follow-up Set: Drug Type and Drug Type and Dose</title>
          <description>Assessment of patients' adherence at Visit 2, for patients who were already adherent at Visit 1, and those who were not adherent at Visit 1, for both drug type and drug type and dose. ESC Criteria for adherence: Drug Types: Treatment with (1) ACEi or (1) ARB in combination with (1) beta-blocker and (1) MRA for patients w/an LVEF ≤ 35% at V1. Treatment w/(1) ACEi or (1) ARB, in combination with (1) beta-blocker+ without treatment with an MRA for patients with an LVEF &gt; 35% at visit 1. Drug type &amp; dose: Guideline adherent with respect to drug types and dosage of all respective guideline drugs ≥ 50% of the recommended target dose.</description>
          <population>Follow-Up set</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adherence at V2, not adherent at V1 for drug type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adherence at V2, not adherent at V1:drug type/dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adherence at V2 and V1 for drug type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adherence at Visit 1 for drug type &amp; dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Heart Failure</title>
        <description>The duration of Heart Failure was collected at Baseline (Visit 1).</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Enrolled Set and Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Patients</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe. Patients who were considered clinically stable an with NT-proBNP levels &gt; 600 pg/ml were referred to a cardiologist for evaluation and were in the follow-up set.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Heart Failure</title>
          <description>The duration of Heart Failure was collected at Baseline (Visit 1).</description>
          <population>Enrolled Set and Follow-Up Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="896"/>
                    <measurement group_id="O2" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≤3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="517"/>
                    <measurement group_id="O2" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Current Use of Concomitant Compound</title>
        <description>Use of concomitant compounds were collected at baseline (Visit 1)</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Enrolled Set and Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Current Use of Concomitant Compound</title>
          <description>Use of concomitant compounds were collected at baseline (Visit 1)</description>
          <population>Enrolled Set and Follow-Up Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diuretics - without mineral corticoid antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="934"/>
                    <measurement group_id="O2" value="625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta blocking agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="981"/>
                    <measurement group_id="O2" value="602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agents acting on the renin-angiotensin system</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="834"/>
                    <measurement group_id="O2" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretics - mineral corticoid antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="664"/>
                    <measurement group_id="O2" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antithrombotic agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401"/>
                    <measurement group_id="O2" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365"/>
                    <measurement group_id="O2" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipid modifying agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mineral supplements</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium channel blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Follow-Up Patients With Current Use of Concomitant Compound at Visit 2</title>
        <description>Use of concomitant compounds were collected at 6 months (Visit 2)</description>
        <time_frame>6 months (Visit 2)</time_frame>
        <population>Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-Up Set Visit 2 (6 Months)</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml were referred to a cardiologist after 6 months (V2) for evaluation and were in the follow-up set</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Follow-Up Patients With Current Use of Concomitant Compound at Visit 2</title>
          <description>Use of concomitant compounds were collected at 6 months (Visit 2)</description>
          <population>Follow-Up Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="753"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diuretics - without mineral corticoid antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta blocking agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agents acting on the renin-angiotensin system</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diuretics - mineral corticoid antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antithrombotic agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipid modifying agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mineral supplements</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium channel blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Clinically Stable Patients for Whom the Cardiologist and/or Primary Care Physician Optimizes Treatment Post Referral, Stratified According to Key Baseline Characteristics</title>
        <description>For patients who enter the prospective period of the study the post-referral treatment choice of cardiologists and/or primary care physicians was documented; for patients, for whom the cardiologist and/or primary care physician chose to prescribe a novel Heart Failure treatment, the treatment was assessed, if it fulfills the definition of adherence to European Society of Cardiology (ESC) guideline recommendation. The proportion of patients for whom an ESC guideline adherent treatment was de novo prescribed was assessed stratified according to different parameters.</description>
        <time_frame>6 months</time_frame>
        <population>Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Clinically Stable Patients for Whom the Cardiologist and/or Primary Care Physician Optimizes Treatment Post Referral, Stratified According to Key Baseline Characteristics</title>
          <description>For patients who enter the prospective period of the study the post-referral treatment choice of cardiologists and/or primary care physicians was documented; for patients, for whom the cardiologist and/or primary care physician chose to prescribe a novel Heart Failure treatment, the treatment was assessed, if it fulfills the definition of adherence to European Society of Cardiology (ESC) guideline recommendation. The proportion of patients for whom an ESC guideline adherent treatment was de novo prescribed was assessed stratified according to different parameters.</description>
          <population>Follow-Up Set</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiologist's advice-No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiologist's advice-Treatment intensification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiologist's advice-Treatment reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiologist's advice-Treatment adaption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Different NT-proBNP Level Categories</title>
        <description>NT-proBNP levels (pg/ml) was measured at baseline in all consecutive patients who satisfy the inclusion and exclusion criteria. Measurements were performed on-site by means of a handheld device provided for the purposes of the study. NT-proBNP level categories could be 600 -799 pg/ml, 800 - 999 pg/ml, 1000 - 1200 pg/ml, &gt; 1200 pg/ml).</description>
        <time_frame>One measurement in all consecutive patients at baseline (Visit 1)</time_frame>
        <population>Enrolled Set and Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Different NT-proBNP Level Categories</title>
          <description>NT-proBNP levels (pg/ml) was measured at baseline in all consecutive patients who satisfy the inclusion and exclusion criteria. Measurements were performed on-site by means of a handheld device provided for the purposes of the study. NT-proBNP level categories could be 600 -799 pg/ml, 800 - 999 pg/ml, 1000 - 1200 pg/ml, &gt; 1200 pg/ml).</description>
          <population>Enrolled Set and Follow-Up Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;600 pg/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 600 pg/ml to &lt;800 pg/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 800 pg/ml to &lt;1000 pg/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1000 pg/ml to &lt;1200 pg/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1200 pg/ml to &lt;1400 pg/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1400 pg/ml to &lt;1600 pg/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1600 pg/ml to &lt;1800 pg/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1800 pg/ml to &lt;2000 pg/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2000 pg/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465"/>
                    <measurement group_id="O2" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Clinically Stable Patients</title>
        <description>Clinically stable patients in this study were defined as those patients for whom the primary care physician did not see a necessity (based on signs and symptoms of HF) to change the current pharmacological and/or device treatment of HF and who were on stable pharmacological and/or device treatment for HF for at least 3 months prior to inclusion.</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Enrolled Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Clinically Stable Patients</title>
          <description>Clinically stable patients in this study were defined as those patients for whom the primary care physician did not see a necessity (based on signs and symptoms of HF) to change the current pharmacological and/or device treatment of HF and who were on stable pharmacological and/or device treatment for HF for at least 3 months prior to inclusion.</description>
          <population>Enrolled Set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients clinically stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients not clinically stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients suitable for prospective period of study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients not suitable for prospective period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients by Cardiologist Prescription Practice Per Country/Region</title>
        <description>The cardiologists' suggestions for pharmacological and/or device therapy for the treatment of clinically stable CHF patients was documented and assessed by means of descriptive statistical measures stratified by country/region 6 months after baseline.</description>
        <time_frame>6 months</time_frame>
        <population>Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients by Cardiologist Prescription Practice Per Country/Region</title>
          <description>The cardiologists' suggestions for pharmacological and/or device therapy for the treatment of clinically stable CHF patients was documented and assessed by means of descriptive statistical measures stratified by country/region 6 months after baseline.</description>
          <population>Follow-Up Set</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Western EU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eastern EU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of NT-proBNP Levels in Clinically Stable Chronic Heart Failure Patients With and Without Treatment Optimization 10 Months After Baseline</title>
        <description>At 10 months after baseline (end of study) NT-proBNP was assessed in clinically stable CHF patients with baseline NT-proBNP levels ≥ 600 pg/ml. Thus, for those patients two NT-proBNP measurements were available: at baseline and 10 months later. The individual change of NT-proBNP between both time points were assessed in accordance to the patients' treatment history during the study, i.e. baseline Heart Failure treatment and therapeutic decision taken 6 months after baseline.</description>
        <time_frame>10 months</time_frame>
        <population>Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of NT-proBNP Levels in Clinically Stable Chronic Heart Failure Patients With and Without Treatment Optimization 10 Months After Baseline</title>
          <description>At 10 months after baseline (end of study) NT-proBNP was assessed in clinically stable CHF patients with baseline NT-proBNP levels ≥ 600 pg/ml. Thus, for those patients two NT-proBNP measurements were available: at baseline and 10 months later. The individual change of NT-proBNP between both time points were assessed in accordance to the patients' treatment history during the study, i.e. baseline Heart Failure treatment and therapeutic decision taken 6 months after baseline.</description>
          <population>Follow-Up Set</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NT-proBNP [pg/ml] at Visit 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2753" spread="2530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NT-proBNP [pg/ml] at Visit 3 (10 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2245" spread="2303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute change in NT-proBNP (V3-V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-504" spread="2607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EuroQol Five Dimensions Questionnaire (EQ-5D) Total and Individual Sub-scores at Visit 1 (Baseline), Visit 2 (6 Months) and Visit 3 (10 Months)</title>
        <description>Quality of life (QoL) was assessed by EQ-5D including the dimensions mobility, self-care, usual activity, pain/discomfort, anxiety/depression. A utility index based on UK value sets was built to summarize the information of these five dimensions into a single scale. The utility index can range between -0.281 and 1.0 where a higher number indicates a better health status. In addition, a visual analog scale (VAS) was applied with a possible range between 0 (=worst imaginable health state) and 100 (=best imaginable health state). Scores collected for all patients at baseline (Visit 1) and at Visit 2 and Visit 3 (only patients who entered the prospective period of the study, i.e. clinically stable patients with a NT-proBNP level ≥ 600 pg/ml) were asked to fill out the EuroQol 5D (EQ-5D) quality of life (QoL) questionnaire validated for heart failure (HF).</description>
        <time_frame>Baseline (Visit 1), 6 months (Visit 2), 10 months (Visit 3)</time_frame>
        <population>Enrolled Set for Visit 1 (Baseline) and Follow-Up Set (Visit 2 and 3) for those clinically stable patients who entered the prospective period of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in EuroQol Five Dimensions Questionnaire (EQ-5D) Total and Individual Sub-scores at Visit 1 (Baseline), Visit 2 (6 Months) and Visit 3 (10 Months)</title>
          <description>Quality of life (QoL) was assessed by EQ-5D including the dimensions mobility, self-care, usual activity, pain/discomfort, anxiety/depression. A utility index based on UK value sets was built to summarize the information of these five dimensions into a single scale. The utility index can range between -0.281 and 1.0 where a higher number indicates a better health status. In addition, a visual analog scale (VAS) was applied with a possible range between 0 (=worst imaginable health state) and 100 (=best imaginable health state). Scores collected for all patients at baseline (Visit 1) and at Visit 2 and Visit 3 (only patients who entered the prospective period of the study, i.e. clinically stable patients with a NT-proBNP level ≥ 600 pg/ml) were asked to fill out the EuroQol 5D (EQ-5D) quality of life (QoL) questionnaire validated for heart failure (HF).</description>
          <population>Enrolled Set for Visit 1 (Baseline) and Follow-Up Set (Visit 2 and 3) for those clinically stable patients who entered the prospective period of the study</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EQ-5D Visual Analog Scale (VAS) - Visit 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1411"/>
                    <count group_id="O2" value="860"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="60" lower_limit="0.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ5D Utility index - Visit 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1411"/>
                    <count group_id="O2" value="860"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="-0.17" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.79" lower_limit="-0.17" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ5D Utility index - Visit 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="747"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.80" lower_limit="-0.11" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ5D Utility index absolute change (V2-V1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="747"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.47" upper_limit="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ5D Utility index - Visit 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="569"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.78" lower_limit="0.28" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ5D Utility index absolute change (V3-V1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="567"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.82" upper_limit="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total and Individual Sub-scores at Visit 1 (Baseline), Visit 2 (6 Months) and Visit 3 (10 Months)</title>
        <description>The KCCQ is a self-administered questionnaire. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and quality of life, each with different Likert scale wording, including limitations, frequency, bother, change in condition, understanding, levels of enjoyment and satisfaction. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. A positive change from baseline indicates improvement. Scores were collected for all patients at baseline and Visit 2 and Visit 3 (only patients who had entered the prospective period of the study (clinically stable patients with a NT-proBNP level ≥ 600 pg/ml) were asked to complete Kansas City Cardiomyopathy Questionnaire (KCCQ) validated for Heart Failure.</description>
        <time_frame>Baseline (Visit 1), 6 months (Visit 2), 10 months (Visit 3)</time_frame>
        <population>Enrolled Set for Visit 1 (Baseline) and Follow-Up Set (Visit 2 and 3) for those clinically stable patients who entered the prospective period of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total and Individual Sub-scores at Visit 1 (Baseline), Visit 2 (6 Months) and Visit 3 (10 Months)</title>
          <description>The KCCQ is a self-administered questionnaire. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and quality of life, each with different Likert scale wording, including limitations, frequency, bother, change in condition, understanding, levels of enjoyment and satisfaction. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. A positive change from baseline indicates improvement. Scores were collected for all patients at baseline and Visit 2 and Visit 3 (only patients who had entered the prospective period of the study (clinically stable patients with a NT-proBNP level ≥ 600 pg/ml) were asked to complete Kansas City Cardiomyopathy Questionnaire (KCCQ) validated for Heart Failure.</description>
          <population>Enrolled Set for Visit 1 (Baseline) and Follow-Up Set (Visit 2 and 3) for those clinically stable patients who entered the prospective period of the study</population>
          <units>Utility Index Score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KCCQ Total Symptom Score - Visit 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1413"/>
                    <count group_id="O2" value="861"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="74.0" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Clinical Summary Score - Visit 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1413"/>
                    <count group_id="O2" value="861"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="68.8" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Overall Summary Score - Visit 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1413"/>
                    <count group_id="O2" value="861"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" lower_limit="4.2" upper_limit="100"/>
                    <measurement group_id="O2" value="66.1" lower_limit="4.2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Overall Summary Score absolute change (V2-V1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="747"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" lower_limit="-48.4" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Overall Summary Score - Visit 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="568"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="66.7" lower_limit="0.0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Overall Summary Score absolute change (V3-V1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="568"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.5" lower_limit="-66.1" upper_limit="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Clinical Summary Score - Visit 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="747"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="68.8" lower_limit="1.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Clinical Summary Score abs. change (V2-V1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="747"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.00" lower_limit="-61.5" upper_limit="65.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Clinical Summary Score - Visit 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="568"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="68.8" lower_limit="0.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Summary Score absolute change (V3-V1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="568"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" lower_limit="-53.1" upper_limit="69.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Different Living Conditions</title>
        <description>Living conditions were collected at Baseline (Visit 1).</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Enrolled Set and Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Different Living Conditions</title>
          <description>Living conditions were collected at Baseline (Visit 1).</description>
          <population>Enrolled Set and Follow-Up Set</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Living independently in household (alone)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313"/>
                    <measurement group_id="O2" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Living with spouse or significant other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="817"/>
                    <measurement group_id="O2" value="481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Living in residence with other family member</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Living in a long term care facility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient housing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Different Employment Status</title>
        <description>Employment status was collected at Baseline (Visit 1).</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Enrolled Set and Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Different Employment Status</title>
          <description>Employment status was collected at Baseline (Visit 1).</description>
          <population>Enrolled Set and Follow-Up Set</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Student</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Employed (part-time)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Employed (full-time)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homemaker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1034"/>
                    <measurement group_id="O2" value="680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unemployed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sustained Sick Leave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Smoking Status</title>
        <description>Smoking status was collected at baseline (visit 1).</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Enrolled Set and Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Smoking Status</title>
          <description>Smoking status was collected at baseline (visit 1).</description>
          <population>Enrolled Set and Follow-Up Set</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="779"/>
                    <measurement group_id="O2" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427"/>
                    <measurement group_id="O2" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients From Different Geographical Regions</title>
        <description>Geographic regions were collected at Baseline (Visit 1).</description>
        <time_frame>Baseline (visit 1)</time_frame>
        <population>Enrolled Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients From Different Geographical Regions</title>
          <description>Geographic regions were collected at Baseline (Visit 1).</description>
          <population>Enrolled Set</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RUS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BEL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MLT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DNK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Health Insurance Status</title>
        <description>Health insurance status was collected at Baseline (Visit 1).</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Enrolled Set and Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Health Insurance Status</title>
          <description>Health insurance status was collected at Baseline (Visit 1).</description>
          <population>Enrolled Set and Follow-Up Set</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Statutory Health Insurance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1168"/>
                    <measurement group_id="O2" value="712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Private Health Insurance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combined statutory and private health insurance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients at Different Educational Level</title>
        <description>Educational level was collected at Baseline (Visit 1).</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Enrolled Set and Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients at Different Educational Level</title>
          <description>Educational level was collected at Baseline (Visit 1).</description>
          <population>Enrolled Set and Follow-Up Set</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Education</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="396"/>
                    <measurement group_id="O2" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Education</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="730"/>
                    <measurement group_id="O2" value="421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>University</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Per Primary Etiology of Heart Failure</title>
        <description>The primary etiology of Heart Failure was collected at Baseline (Visit 1).</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Enrolled Set and Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Per Primary Etiology of Heart Failure</title>
          <description>The primary etiology of Heart Failure was collected at Baseline (Visit 1).</description>
          <population>Enrolled Set and Follow-Up Set</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Etiology- Ischemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="860"/>
                    <measurement group_id="O2" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary Etiology-Non-Ischemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="553"/>
                    <measurement group_id="O2" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Heart Failure (HF)-Related Hospitalizations in the Previous 12 Months Prior to Baseline, and During the Study</title>
        <description>HF-related hospitalizations was collected in the previous 12 months prior to baseline at baseline visit, at 6 and 10 months post-baseline.</description>
        <time_frame>Baseline (Visit 1), 6 months, 10 months</time_frame>
        <population>Enrolled Set and Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Heart Failure (HF)-Related Hospitalizations in the Previous 12 Months Prior to Baseline, and During the Study</title>
          <description>HF-related hospitalizations was collected in the previous 12 months prior to baseline at baseline visit, at 6 and 10 months post-baseline.</description>
          <population>Enrolled Set and Follow-Up Set</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1- Up to Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383"/>
                    <measurement group_id="O2" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2-6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3-10 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Cardiovascular and Non-cardiovascular Co-morbidities</title>
        <description>Cardiovascular and non-cardiovascular co-morbidities were collected at baseline (Visit 1)</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Enrolled Set and Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Cardiovascular and Non-cardiovascular Co-morbidities</title>
          <description>Cardiovascular and non-cardiovascular co-morbidities were collected at baseline (Visit 1)</description>
          <population>Enrolled Set and Follow-Up Set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1415"/>
                <count group_id="O2" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2"/>
                    <measurement group_id="O2" value="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyslipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6"/>
                    <measurement group_id="O2" value="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9"/>
                    <measurement group_id="O2" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8"/>
                    <measurement group_id="O2" value="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obesity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1"/>
                    <measurement group_id="O2" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable angina pectoris</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4"/>
                    <measurement group_id="O2" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes mellitus type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Comorbidities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Dose of Previously Taken and Current Use of Concomitant Medications</title>
        <description>Mean Dose of previously taken and current use of concomitant medications was to be collected at Visit 1, 6 months, 10 months post-baseline</description>
        <time_frame>Baseline (Visit 1), 6 months, 10 months</time_frame>
        <population>Enrolled Set and Follow-Up Set (Mean dose of concomitant medications was not collected/provided and could not be alternately computed based upon the information listed).</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled Set</title>
            <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
          </group>
          <group group_id="O2">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Dose of Previously Taken and Current Use of Concomitant Medications</title>
          <description>Mean Dose of previously taken and current use of concomitant medications was to be collected at Visit 1, 6 months, 10 months post-baseline</description>
          <population>Enrolled Set and Follow-Up Set (Mean dose of concomitant medications was not collected/provided and could not be alternately computed based upon the information listed).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Heart Failure (HF) Treatment Combinations</title>
        <description>The types and number of participants with HF treatment combinations were collected at Baseline (Visit 1).</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Follow-Up Set: Patients who were considered clinically stable and had NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Baseline (Visit 1) for evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Heart Failure (HF) Treatment Combinations</title>
          <description>The types and number of participants with HF treatment combinations were collected at Baseline (Visit 1).</description>
          <population>Follow-Up Set: Patients who were considered clinically stable and had NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Baseline (Visit 1) for evaluation.</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>One ACEi or one ARB and one beta-blocker(V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one beta-blocker and one MRA(V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one ACEi or one ARB and one MRA(V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One ACEi or (1)ARB &amp; (1)MRA &amp; (1)beta-blocker(V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one beta-blocker and ARNi(V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one MRA and ARNi(V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one MRA and one beta-blocker and ARNi(V1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One ACEi or one ARB and one beta-blocker(V2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one beta-blocker and one MRA(V2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one ACEi or one ARB and one MRA(V2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One ACEi or (1)ARB &amp; (1)MRA &amp; (1)beta-blocker(V2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one beta-blocker and ARNi(V2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one MRA and ARNi(V2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one MRA and one beta-blocker and ARNi(V2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One ACEi or one ARB and one beta-blocker(V3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one beta-blocker and one MRA(V3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one ACEi or one ARB and one MRA(V3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One ACEi or (1)ARB &amp; (1)MRA &amp; (1)beta-blocker(V3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one beta-blocker and ARNi(V3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one MRA and ARNi(V3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exactly one MRA and one beta-blocker and ARNi(V3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Treatment With Device Type</title>
        <description>The duration of treatment with device type was collected at baseline (Visit 1)</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Follow-Up Set (Data was not collected for this endpoint)</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Treatment With Device Type</title>
          <description>The duration of treatment with device type was collected at baseline (Visit 1)</description>
          <population>Follow-Up Set (Data was not collected for this endpoint)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Previously Taken and Currently Use of Most Common Non-Heart Failure Concomitant Compounds</title>
        <description>Duration of most common previously taken and current use of most common Non-HF concomitant compounds were collected</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Follow-Up Set</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Previously Taken and Currently Use of Most Common Non-Heart Failure Concomitant Compounds</title>
          <description>Duration of most common previously taken and current use of most common Non-HF concomitant compounds were collected</description>
          <population>Follow-Up Set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Antithrombotic agents -≤1 and &gt;3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipid modifying agents -≤1 and &gt;3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drugs for acid related disorders-≤1 and &gt;3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients by Primary Care Physicians' Prescription Practice Per Country/Region</title>
        <description>For clinically stable CHF patients, the primary care physicians' prescription of pharmacological and device treatment for HF was to be documented prior to baseline and post cardiologist-referral. At the post-referral visit the degree of implementation of cardiologist-recommendations and the medical decision making (e.g. reasons for non-implementation) were to be documented.</description>
        <time_frame>Baseline (Visit 1)</time_frame>
        <population>Follow-Up Set (Data was not collected for this endpoint.)</population>
        <group_list>
          <group group_id="O1">
            <title>Follow-Up Set</title>
            <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients by Primary Care Physicians' Prescription Practice Per Country/Region</title>
          <description>For clinically stable CHF patients, the primary care physicians' prescription of pharmacological and device treatment for HF was to be documented prior to baseline and post cardiologist-referral. At the post-referral visit the degree of implementation of cardiologist-recommendations and the medical decision making (e.g. reasons for non-implementation) were to be documented.</description>
          <population>Follow-Up Set (Data was not collected for this endpoint.)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from FPFV to LPLV up to 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Enrolled Set</title>
          <description>Adult male and female patients with chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who were managed in a primary care setting in sites across Europe.</description>
        </group>
        <group group_id="E2">
          <title>Follow-Up Set</title>
          <description>Patients who were considered clinically stable and with NT-proBNP levels &gt; 600 pg/ml who were referred to a cardiologist at Visit 1 for evaluation were in the follow-up set.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Short-bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Soft tissue inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Intestinal gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Homicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Aortic valve repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cardiac ablation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cardiac resynchronisation therapy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Accommodation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Sudden visual loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Viral sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Blood pressure abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>N-terminal prohormone brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Vitamin B12 decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dyspnoea paroxysmal nocturnal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Nocturnal dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Dental operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Intraocular lens implant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1415"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The recruitment was to be regarded as completed once approx. 2400 patients had entered the prospective period. However it was decided by Novartis to terminate the study prematurely, in March 2018.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

